Hollard D, Sotto J J, Bachelot C, Michallet M, Ribaud P, Schaerer R, Waguet J C
Nouv Presse Med. 1976 May 15;5(20):1289-93.
Addition of a daily dose of androgen in the form of 0.15 mg/kg of Stanzolol, given without interruption, gave an average survival of more than 4 years in patients suffering from granulocyte series acute leukaemias after complete remission was obtained. The simplicity of this treatment is apparent only from the appearance of marked manifestations of androgen impregnation in women from the 8th month of treatment onwards. These results, superior to those obtained up to the present time in the survival of myeloid leukaemias (non-lymphoblastic) were also better in terms of the stability and X "quality" of the remission in comparison to those obtained in acute lymphoblastic leukaemias. Confirmation of these results by controlled clinical trial will open up interesting perspectives, along side immunotherapy which remains of unproven effectiveness in myeloid leukaemias. The effectiveness of androgen stimulation of haematopoiesis as a stabilising factor of complete remissions in acute leukaemias has, in addition, interesting implications with regard to the theory of the leukaemic process.
对于粒细胞系列急性白血病患者，在完全缓解后，每天以0.15毫克/千克司坦唑醇的形式不间断给予雄激素，其平均生存期超过4年。这种治疗方法的简单性仅从治疗第8个月起女性出现明显的雄激素浸润表现才显现出来。这些结果优于目前在髓系白血病（非淋巴细胞性）生存方面所获得的结果，并且在缓解的稳定性和“质量”方面也优于急性淋巴细胞白血病所获得的结果。通过对照临床试验对这些结果的证实将开辟有趣的前景，同时免疫疗法在髓系白血病中的有效性仍未得到证实。此外，雄激素刺激造血作为急性白血病完全缓解的稳定因素的有效性，对于白血病发生过程的理论具有有趣的启示。
